Journal of Commercial Biotechnology <h2 style="margin: 0 0 .5em; font-weight: 300;">Leading thinking on biotechnology business management</h2> <p style="margin-top: 3px;">The <em>Journal of Commercial Biotechnology</em>, in print since 1994, is the definitive international quarterly publication for life sciences business professionals. The Journal is designed specifically for those professionals who need to enhance their knowledge of business strategy and management, improve and advance their product development, or those who want to keep up-to-date with current issues and industry trends. Our focus is on the life science industries, e.g. biopharma (biotechnology &amp; pharmaceuticals, MedTech and digital health; and on food and agricultural products and services to improve organisms.</p> <p>Each issue publishes peer-reviewed, authoritative, cutting-edge articles and perspectives (“Biotechnology Industry Perspectives”; and ”Bioentrepreneurship University Insights”) written by the leading practitioners and researchers in the field. We publish both submitted and solicited articles (including special editions), addressing topics such as:</p> <ul> <li>Management, Leadership, and collaborative teams</li> <li>Commercialization, Marketing, and Innovation strategies and best practices</li> <li>Entrepreneurship, including education</li> <li>Policy</li> <li>Finance &amp; transactions associated with founding, building, partnering and exiting</li> <li>Law, Intellectual Property, Regulation, Reimbursement</li> <li>Bioethics</li> </ul> <p style="background: white;"><span style="font-size: 10.5pt; font-family: 'Arial',sans-serif;">The <em><span style="font-family: 'Arial',sans-serif;">Journal of Commercial Biotechnology</span></em> is a unique forum for all those involved in life sciences commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast-moving and diverse field.</span></p> en-US <p>Unless specified by prior arrangement, the author agrees to the following terms and assurances:</p><ol><li>For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.</li><li>I/we further give to the following assurances<ol><li>I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;</li><li>I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;</li><li>To the best of my/our knowledge, all the facts in the contribution are true and accurate;</li><li>The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);</li><li>Nothing in the contribution is obscene or libellous;</li><li>Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.</li><li>I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).</li></ol></li></ol>* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment. (Art Boni) (Publisher: Yali Friedman) Thu, 23 Dec 2021 01:27:14 +0000 OJS 60 The Role of the Biotechnology Industry in Addressing Health Inequities in Africa: Strengthening the Entire Health Care Value Chain <p>There are many misconceptions surrounding health care in Africa, a continent of 54 sovereign countries and a population exceeding 1.2 billion souls which is growing at the fastest rate in the world. Enormous diversity has direct impact on the notion, practices, and availability of health care on the continent. There are no satisfactory generalizations about the state of health and the strength of health care systems for the continent as a whole. Indeed, differences between neighboring countries are enormous, as well as among population groups within countries. There is a significant mix of public, private, and faith-based health care providers. In most African countries, 60 percent of health providers fall into the latter two categories (IFC, 2008). Moreover, movements towards national and private risk pooling for payment of health care are underway in only a few countries, but virtually all modern African constitutions declare health care as a human right and aspire to some form of Universal Health Coverage (UHC). Despite these principles, Africans endure a dual burden of communicable and non-communicable disease. In the face of these challenges, Africans are confronted with out-of-pocket payment for health services – when it is available at all – and challenging logistics for accessing and maintaining consistency of care. The patient journey for Africans is a winding path, often exacerbated by an additional reliance on the importation of talent, pharmaceuticals and vaccines, medical and diagnostic tools, and digital support of the health systems. The health care value chain in Africa is incomplete. Each of Providers, Payers and Producers need further development. When any of these is weak or missing, there cannot be a sustainable health system. The issue, therefore, is not scientific or clinical competence; it is capacity and the necessity to promote a comprehensive and integrated health care ecosystem – including the Producer segment. To address the Producer link, more direct engagement by the global biopharmaceutical industry in assisting and investing in the advancement of indigenous laboratory and clinical development, product production and distribution, and the advancement of human capital necessary to achieve health care sovereignty for the continent is necessary. There is all the more reason to do so as humanity enters the age of genomic and precision medicine. There is a pathway for African health care to leapfrog as it has done in telecommunications.</p> Stephen M. Sammut Copyright (c) 2021 Journal of Commercial Biotechnology Thu, 23 Dec 2021 00:00:00 +0000 Considerations for Potential Global Expansion of Serum Institute of India <p>In a time of global vaccine shortages, especially for COVID-19 products, Serum Institute of India (SII) is straining to meet demand for vaccines in India. While this organization is not known worldwide, they entered into a recent alliance with AstraZeneca, who is partnered with Oxford University for Covid-19 vaccine, to manufacture their supply of vaccines for distribution in India. Several other such partnerships are also underway. And, SII is considering plans to become a much larger player, not only in India, but globally. This commentary is focused on if, when, where, why, and how global expansion could proceed. Our work was carried out as a class project to identify options and strategies appropriate for expansion and has been expanded subsequently as events continued to develop.</p> Veena Somasundaram, Peter Soukas, Jenish Patel, Steven Ferguson Copyright (c) 2021 Journal of Commercial Biotechnology Thu, 23 Dec 2021 00:00:00 +0000 Drug Repositioning as a Pharmaceutical Strategy: The Obvious Benefits are Real but Beware of Pitfalls That May be Less Apparent. <p>For the last 15 years the drug discovery strategy referred to as “drug-repositioning” has been a recognized approach towards bringing new therapeutics to market and has continued to grow in popularity over this time frame.&nbsp; Melior Discovery is a company with a founding mission centered on drug repositioning.&nbsp; The author shares his perspective on lessons learned over 15 years of conducting drug repositioning efforts, complete with advantages and disadvantages that he has encountered using this approach and why, overall, this means of drug discovery provides a compelling business rationale.</p> Andrew G. Reaume Copyright (c) 2021 Journal of Commercial Biotechnology Thu, 23 Dec 2021 00:00:00 +0000 Strategic Alliance and Acquisition Performance: Impact of Interfirm Synergies and Motives in the Bio-Pharmaceutical Industry <p>This study draws on transaction cost, resource dependence, and organizational learning theories to posit relationships between transaction performance and transaction structure (alliances versus acquisitions), interfirm synergies, and motives. The study involves analysis of 66 international and intra­national alliances and acquisitions that were undertaken in the pharmaceutical industry. An initial survey was administered to firms involved in these transactions to gather information regarding motives, transaction structure, and interorganizational synergies. A second survey was administered two years after the transaction to gather information on transaction performance. Findings support the importance of transaction structure and strategic synergies between firms. Specifically, transaction structure and high levels of strategic fit between the firms had a positive impact on performance. There is also some evidence that synergies must be linked to the motives driving the transaction. The study yields meaningful results regarding factors leading to success of transactions (alliances and&nbsp; acquisitions)&nbsp; in a&nbsp; longitudinal&nbsp; study&nbsp; of&nbsp; intranational and international transactions in the biopharmaceutical industry.</p> Thani Jambulingam, Todd Saxton Copyright (c) 2021 Journal of Commercial Biotechnology Thu, 23 Dec 2021 00:00:00 +0000 Australian Biotechnology: A 10-Year Study of Investor Performance <p class="Abstract">A recent study assessed the investor performance of the Australian drug development biotech (DDB) sector over a 15-year period from 2003 to 2018. The current study builds on that research and extends the analysis to 2020, using a 10-year period starting 2010, to exclude the impact of the global financial crisis in 2008/09. Based on a value-weighted portfolio of all 41 DDB firms, the overall sector delivered a negative annualized return of -4.1%. Individual firm performance was also assessed using the compound annual growth rate (CAGR) in share price over the period as a measure of investor outcomes. On this basis 68% of firms produced negative CAGRs over the period, and of the 32% of firms that produced positive CAGRs, six firms produced CAGRs greater than 20% per annum and in three cases of recently-listed firms, the CAGR’s were greater than 50%. Overall however, the sector overall delivered very poor investor returns and despite a relatively large number of listed biotech firms, Australian biotechnology continues to be small and weak in terms of its contribution to global biotechnology industrialization. As such it lacks the critical mass to grow a robust bioeconomy based on drug development, which remains the standard-bearer of biotechnology industrialization.</p> Peter L. Molloy , Lester W. Johnson, Michael Gilding Copyright (c) 2021 Journal of Commercial Biotechnology Thu, 23 Dec 2021 00:00:00 +0000 A conversation on accelerating innovation in biopharma and life sciences through global collaboration and alliances <p>We note and reflect on the power of international partnering and collaborations that led to many of the innovations that were brought to market extremely quickly and successfully during the Covid-19 pandemic. These collaborative global approaches suggest the potential for developing broader, open innovation models in more extensive regional and global collaborations for other biopharma and life science market segments. In this article, we adopt a ‘virtual panel discussion format” to frame and discuss potential issues and models that would need to be designed, developed and tested, with the purpose of engaging emerging global regions as equal partners. We also consider similar challenges for regions within countries – even in the US - that lack significant sources for capital across the company life cycle.&nbsp; Several recent open innovation alliance approaches or models are discussed as potential models.&nbsp; They are: the Eli Lilly FIP Net (fully integrated pharmaceutical network); the Enlight Bioscience alliance developed by Pure Tech Ventures; the Harrington Project linking academia to industry; and, the Corporate Accelerator model notably recently expanded globally by Illumina. We outline a proposal to create a guiding coalition, or “think tank” to further test and develop the proposals discussed herein.</p> Arthur A Boni, Peter L. Molloy Copyright (c) 2021 Journal of Commercial Biotechnology Thu, 23 Dec 2021 00:00:00 +0000 A Note From the Editor in Chief Arthur A Boni Copyright (c) 2021 Journal of Commercial Biotechnology Thu, 23 Dec 2021 00:00:00 +0000